GlaxoSmithKline announced it is set to acquire preclinical-stage biotech firm Sitari Pharmaceuticals, although no financial details of the takeover were disclosed. Sitari was founded in 2013 by GSK and Avalon Ventures and its lead candidate is a TG2 inhibitor designed to treat celiac disease, an autoimmune digestive disorder.
GSK to acquire celiac therapy developer Sitari Pharmaceuticals
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.